News

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...
Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...
In a sector where trust is critical, and attention is limited, that feeling matters. Frictionless design isn’t just about ...
The Evolution Summit is designed to address the most pressing challenges and opportunities in clinical trials, with a focus ...
Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous ...
US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove ...
Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...
Agentic AI refers to AI systems that add layers of reason and autonomy. They act as largely independent agents that are ...
The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to ...
June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.
On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...
The second healthcare sector IPCEI – approving up to €403 million of State aid by five Member States, including France, ...